Orexigen Therapeutics Inc $5.29

down -0.07


25/7/2014 04:00 PM  |  NASDAQ : OREX  
Industries : Drugs / Drug Manufacturers - Other
Get Trend Analysis Icon Get OREX Trend Analysis - it has underperformed the S&P 500 by 43%

Partner Headlines

  1. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  2. FDA delays Orexigen drug

    IBD
  3. Mid-Afternoon Market Update: ULTA Salon Remains Steady After Strong Results; ...

    Benzinga
  4. Mid-Day Market Update: ULTA Salon Rises After Strong Results; Orexigen ...

    Benzinga
  5. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  6. Orexigen Shares Plummet Following FDA Decision; Competition Gets A Bump

    Benzinga
  7. Mid-Morning Market Update: Markets Drop; H&R Block Posts Higher Profit

    Benzinga
  8. Morning Market Losers

    Benzinga
  9. Benzinga's Top #PreMarket Losers

    Benzinga
  10. US Stock Futures Tumble; World Bank Lowers Global Growth Outlook

    Benzinga
  11. Earnings Scheduled For March 12, 2014

    Benzinga
  12. Benzinga's Top #PreMarket Losers

    Benzinga
  13. Benzinga's Top #PreMarket Gainers

    Benzinga
  14. Mid-Afternoon Market Update: Markets Turn Back as Momentum Stocks Drop

    Benzinga
  15. Mid-Day Market Update: SeaDrill Drops On Downbeat Earnings; Giant Interactive ...

    Benzinga
  16. Benzinga's Top #PreMarket Gainers

    Benzinga
  17. Orexigen Announces Successful Interim Analysis of Contrave Light Study, ...

    Benzinga
  18. Orexigen, Takeda Report Multiple Contrave Data Presentations at ObesityWeek

    Benzinga
  19. Obesity drugs up on report

    IBD
  20. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and Raises PT

    Benzinga
  21. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  22. Benzinga's Top Initiations

    Benzinga
  23. Orexigen Submits Contrave Marketing Authorization Application to EMA

    Benzinga
  24. Mid-Afternoon Market Update: DSW Rises as the NASDAQ Gets Crushed

    Benzinga
  25. Benzinga's Top Pre-Market Gainers

    Benzinga
  26. Orexigen Reports Progress on Resubmission of Contrave NDA, Sees Potential ...

    Benzinga
  27. Orexigen Concludes Light Study Patient Screening, to Randomize ~9,000 Patients, ...

    Benzinga
  28. Orexigen Therapeutics Inc. Reports Operating Results (10-Q)

    GuruFocus
  29. Orexigen Therapeutics Announces Proposed Public Offering of Common Stock

    Benzinga
  30. Orexigen Therapeutics Receives Positive Dispute Response from FDA for Contrave

    Benzinga
  31. Who Needs Diet and Exercise? Health Plans Cover New Vivus Obesity Drug

    YCharts
  32. Benzinga's Top Pre-Market Losers

    Benzinga
  33. US Stock Futures Down; Crude Oil Drops

    Benzinga
  34. Stocks To Watch For September 17, 2012

    Benzinga
  35. Benzinga's Top Initiations

    Benzinga
  36. Benzinga's Top Pre-Market Gainers

    Benzinga
  37. Orexigen Therapeutics Announces Continued Rapid Enrollment into the Light ...

    Benzinga
  38. Orexigen Therapeutics Inc. (OREX) President and CEO Michael Narachi sells ...

    GuruFocus
  39. Benzinga's Top Pre-Market Gainers

    Benzinga
  40. Vivus Rises Ahead Of FDA Vote On Qnexa Diet Drug

    IBD
  41. Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, ...

    GuruFocus
  42. Orexigen Therapeutics Inc. (OREX) President and CEO Michael Narachi sells ...

    GuruFocus
  43. UPDATE: Bank of America Raises PT on Orexigen Therapeutics from $7 to $9.

    Benzinga
  44. Benzinga's Top Pre-Market Gainers

    Benzinga
  45. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than ...

    Benzinga
  46. Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples ...

    GuruFocus
  47. These Are Four of the Hottest Biotechs in the Market Right Now

    Benzinga
  48. Orexigen Therapeutics Falls 6% on Profit Taking

    Benzinga
  49. Orexigen Therapeutics (OREX) Up 11% After FDA OKs Rival Anti-Obesity Drug

    MarketIntelligenceCenter
  50. Obesity Drug Stocks Go Wild After Belviq Approval

    IBD
Trading Center